TY - JOUR
T1 - Sodium Salts and Solvate of Rebamipide
T2 - Synthesis, Structure, and Pharmacokinetic Study
AU - Chi, Yingnan
AU - Liu, Chuanrong
AU - Ren, Tianming
AU - Wang, Xiaoying
AU - Yang, Qiuhong
AU - Yang, Zhichao
AU - Yang, Yan
AU - Yang, Song
AU - Gu, Jingkai
AU - Hu, Changwen
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Two sodium salts (Na(CH3CH2OH) (HReb) (1) and Na2(H2O)4(Reb) (2)), one methanol solvate (H2Reb·CH3OH (3)), and one methyl ester (4) of the minimally soluble drug, rebamipide (H2Reb), used for the treatment of gastric ulcers and gastritis have been synthesized. For the first time the structure of rebamipide has been determined by single crystal X-ray diffraction. Although salts 1 and 2 were prepared under the similar conditions, their structures are different. In 1, rebamipide loses the proton of the carboxyl group to interact with the sodium ion, but in 2 the drug molecule converts to its prototropic tautomer and then simultaneously loses the protons of the carboxyl and hydroxyl groups to form salt. Control experiments show that reaction temperature is the key factor influencing the formation of salts. Although all methanol was used in the synthesis of 3 and 4, in 3 methanol acts as solvent involved in the lattice, while in 4 it reacts with rebamipide to form ester. By analyzing the mass spectra of the reaction solution, we speculate that the crystallization of 3 and 4 is controlled by the products solubility. Dissolution studies indicate that both the maximum solubility and dissolution rate of 1-4 in simulated succus gastricus are improved. Furthermore, pharmacokinetic behavior of compounds 1-4 was investigated in rats and the results indicate that the bioavailability of 1, 3, and 4 upon oral administration is enhanced compared to that of API.
AB - Two sodium salts (Na(CH3CH2OH) (HReb) (1) and Na2(H2O)4(Reb) (2)), one methanol solvate (H2Reb·CH3OH (3)), and one methyl ester (4) of the minimally soluble drug, rebamipide (H2Reb), used for the treatment of gastric ulcers and gastritis have been synthesized. For the first time the structure of rebamipide has been determined by single crystal X-ray diffraction. Although salts 1 and 2 were prepared under the similar conditions, their structures are different. In 1, rebamipide loses the proton of the carboxyl group to interact with the sodium ion, but in 2 the drug molecule converts to its prototropic tautomer and then simultaneously loses the protons of the carboxyl and hydroxyl groups to form salt. Control experiments show that reaction temperature is the key factor influencing the formation of salts. Although all methanol was used in the synthesis of 3 and 4, in 3 methanol acts as solvent involved in the lattice, while in 4 it reacts with rebamipide to form ester. By analyzing the mass spectra of the reaction solution, we speculate that the crystallization of 3 and 4 is controlled by the products solubility. Dissolution studies indicate that both the maximum solubility and dissolution rate of 1-4 in simulated succus gastricus are improved. Furthermore, pharmacokinetic behavior of compounds 1-4 was investigated in rats and the results indicate that the bioavailability of 1, 3, and 4 upon oral administration is enhanced compared to that of API.
UR - http://www.scopus.com/inward/record.url?scp=84973325012&partnerID=8YFLogxK
U2 - 10.1021/acs.cgd.5b01839
DO - 10.1021/acs.cgd.5b01839
M3 - Article
AN - SCOPUS:84973325012
SN - 1528-7483
VL - 16
SP - 3180
EP - 3189
JO - Crystal Growth and Design
JF - Crystal Growth and Design
IS - 6
ER -